IP Library › Granted Patent US 9,296,701
Granted Patent B2
US 9,296,701 · App. 13/868,703 · Granted Mar 29, 2016

DNA-PK inhibitors

Inventors: Paul S Charifson (Farmingham, MA); Kevin Michael Cottrell (Cambridge, MA); Hongbo Deng (Southborough, MA); John P. Duffy (Northborough, MA); Huai Gao (Arlington, MA); Simon Giroux (Cambridge, MA); Jeremy Green (Waltham, MA); Katrina Lee Jackson (Cambridge, MA); Joseph M Kennedy (Charlestown, MA); David J. Lauffer (Stow, MA); Mark Willem Ledeboer (Acton, MA); Pan Li (Lexington, MA); John Patrick Maxwell (Hingham, MA); Mark A. Morris (Somerville, MA); Albert Charles Pierce (Cambridge, MA); Nathan D. Waal (Cambridge, MA); Jinwang Xu (Framingham, MA)
Assignee: Vertex Pharmaceuticals Incorporated
C07D239/42A61K41/0038A61K47/481C07D401/04C07D401/14C07D403/04C07D403/10C07D405/14C07D409/04C07D409/14C07D413/04C07D413/10C07D413/14C07D417/04C07D417/10C07D417/14C07D471/04C07D491/048C07D491/056C07D495/04C07D521/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,296,701
App. No.
13/868,703
Granted
Mar 29, 2016
Kind
B2
Abstract

The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

Claims (18)

1. A compound, wherein the compound is

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable excipient.

3. The compound of claim 1 , represented by the following formula or a pharmaceutically acceptable salt thereof:

4. The compound of claim 1 , represented by the following formula or a pharmaceutically acceptable salt thereof:

5. The compound of claim 1 , represented by the following formula or a pharmaceutically acceptable salt thereof:

6. A compound represented by the following formula:

7. The compound of claim 1 , represented by the following formula or a pharmaceutically acceptable salt thereof:

8. The compound of claim 1 , represented by the following formula or a pharmaceutically acceptable salt thereof:

9. The compound of claim 1 , represented by the following formula or a pharmaceutically acceptable salt thereof:

10. The compound of claim 1 , represented by the following formula or a pharmaceutically acceptable salt thereof:

11. A compound represented by the following formula:

12. The compound of claim 1 , represented by the following formula or a pharmaceutically acceptable salt thereof:

13. The compound of claim 1 , represented by the following formula or a pharmaceutically acceptable salt thereof:

14. A pharmaceutical composition comprising a compound according to claim 5 and a pharmaceutically acceptable excipient.

15. A pharmaceutical composition comprising a compound according to claim 6 and a pharmaceutically acceptable excipient.

16. A pharmaceutical composition comprising a compound according to claim 10 and a pharmaceutically acceptable excipient.

17. A pharmaceutical composition comprising a compound according to claim 11 and a pharmaceutically acceptable excipient.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Oct 14, 2016
From: MACQUARIE US TRADING LLC
To: VERTEX PHARMACEUTICALS INCORPORATED; VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
Reel/Frame 040357/0001 →
SECURITY INTEREST Recorded Jul 10, 2014
From: VERTEX PHARMACEUTICALS INCORPORATED; VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 033292/0311 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2013
From: CHARIFSON, PAUL S.; COTTRELL, KEVIN MICHAEL; DENG, HONGBO; DUFFY, JOHN P.; GAO, HUAI; GIROUX, SIMON; GREEN, JEREMY; JACKSON, KATRINA LEE; KENNEDY, JOSEPH M.; LAUFFER, DAVID J.; LEDEBOER, MARK WILLEM; LI, PAN; MAXWELL, JOHN PATRICK; MORRIS, MARK A.; PIERCE, ALBERT CHARLES; WAAL, NATHAN D.; XU, JINWANG
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 030894/0361 →
Continuity (4)
Provisional Application 61637512 · Apr 24, 2012
Provisional Application 61725652 · Nov 13, 2012
Provisional Application 61777806 · Mar 12, 2013
Related Publication 20130281431A1 · Oct 24, 2013